The first round of chemotherapy in high-risk neuroblastoma patients – St. Baldrick’s Foundation
St. Baldrick’s Foundation shared a post on LinkedIn about a recent paper by Elizabeth Sokol et al. published in EJC Paediatric Oncology:
“In high-risk neuroblastoma patients, their response to the first round of chemotherapy can provide doctors with valuable insights into their chances of recovery.
A recent study by the Children’s Oncology Group revealed that certain factors, such as the tumor’s origin and specific genetic changes, were associated with poorer outcomes in patients who didn’t respond well to treatment.
Conversely, patients who responded positively had fewer of these factors impacting their survival.”
Authors: Elizabeth Sokol, Brian LaBarre, Navin Pinto, Susan Kreissman, Meaghan Granger, Julie Park, Rochelle Bagatell, Arlene Naranjo, Steven DuBois.
More posts featuring St. Baldrick’s Foundation.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023